S&P 500   3,113.01 (+0.53%)
DOW   27,917.75 (+0.49%)
QQQ   202.49 (+0.53%)
CGC   15.28 (-3.54%)
BABA   185.30 (+1.37%)
GE   11.50 (+1.86%)
T   39.29 (+0.85%)
ACB   2.88 (-12.46%)
F   8.96 (+1.94%)
BAC   32.88 (+0.52%)
DIS   144.94 (-1.50%)
S&P 500   3,113.01 (+0.53%)
DOW   27,917.75 (+0.49%)
QQQ   202.49 (+0.53%)
CGC   15.28 (-3.54%)
BABA   185.30 (+1.37%)
GE   11.50 (+1.86%)
T   39.29 (+0.85%)
ACB   2.88 (-12.46%)
F   8.96 (+1.94%)
BAC   32.88 (+0.52%)
DIS   144.94 (-1.50%)
S&P 500   3,113.01 (+0.53%)
DOW   27,917.75 (+0.49%)
QQQ   202.49 (+0.53%)
CGC   15.28 (-3.54%)
BABA   185.30 (+1.37%)
GE   11.50 (+1.86%)
T   39.29 (+0.85%)
ACB   2.88 (-12.46%)
F   8.96 (+1.94%)
BAC   32.88 (+0.52%)
DIS   144.94 (-1.50%)
S&P 500   3,113.01 (+0.53%)
DOW   27,917.75 (+0.49%)
QQQ   202.49 (+0.53%)
CGC   15.28 (-3.54%)
BABA   185.30 (+1.37%)
GE   11.50 (+1.86%)
T   39.29 (+0.85%)
ACB   2.88 (-12.46%)
F   8.96 (+1.94%)
BAC   32.88 (+0.52%)
DIS   144.94 (-1.50%)
Log in

TransMedics Group Stock Price, Forecast & Analysis (NASDAQ:TMDX)

$18.49
+0.62 (+3.47 %)
(As of 11/15/2019 02:00 PM ET)
Today's Range
$18.00
Now: $18.49
$18.64
50-Day Range
$16.61
MA: $18.80
$23.80
52-Week Range
$15.74
Now: $18.49
$31.54
Volume4,593 shs
Average Volume131,247 shs
Market Capitalization$391.25 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
TransMedics, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation. Its Organ Care System preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Its Organ Care System incudes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains organs in a near physiologic state and enables surgeons to perfuse and ventilate the organ between the donor and recipient sites; OCS Heart, a portable heart perfusion system that helps to maintain organs in a warm functioning state outside of the body; and OCS Liver, a portable perfusion and monitoring system that maintains organs in a near physiologic state. The company offers its products in the United States and internationally. TransMedics, Inc. is headquartered in Andover, Massachusetts. TransMedics, Inc. is a subsidiary of Transmedics Group, Inc.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TMDX
CUSIPN/A
CIKN/A
Phone978-552-0900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.00 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$391.25 million
Next Earnings Date2/5/2020 (Estimated)
OptionableNot Optionable

Receive TMDX News and Ratings via Email

Sign-up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter.


TransMedics Group (NASDAQ:TMDX) Frequently Asked Questions

What is TransMedics Group's stock symbol?

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

How were TransMedics Group's earnings last quarter?

TransMedics Group Inc (NASDAQ:TMDX) issued its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.47) by $0.08. The business had revenue of $7.21 million for the quarter, compared to analyst estimates of $6.67 million. View TransMedics Group's Earnings History.

When is TransMedics Group's next earnings date?

TransMedics Group is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for TransMedics Group.

What price target have analysts set for TMDX?

4 brokerages have issued 12-month price targets for TransMedics Group's stock. Their forecasts range from $28.00 to $37.00. On average, they expect TransMedics Group's stock price to reach $33.00 in the next year. This suggests a possible upside of 78.5% from the stock's current price. View Analyst Price Targets for TransMedics Group.

What is the consensus analysts' recommendation for TransMedics Group?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TransMedics Group.

Has TransMedics Group been receiving favorable news coverage?

Press coverage about TMDX stock has trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. TransMedics Group earned a coverage optimism score of -1.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for TransMedics Group.

Who are some of TransMedics Group's key competitors?

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include AbbVie (ABBV), Spotify (SPOT), AT&T (T), Aviva (AV), Alexion Pharmaceuticals (ALXN), Amarin (AMRN), Craft Brew Alliance (BREW), Marvell Technology Group (MRVL), Micron Technology (MU) and PepsiCo (PEP).

Who are TransMedics Group's key executives?

TransMedics Group's management team includes the folowing people:
  • Dr. Waleed H. Hassanein, Pres, CEO & Director (Age 51)
  • Mr. Stephen Gordon, CFO, Treasurer & Sec. (Age 51)
  • Mr. John F. Carey, VP of Operations (Age 55)
  • Mr. Ike Okonkwo, VP of Fin. & Accounting (Age 48)
  • Mr. Brian Thomson, VP of HR (Age 51)

When did TransMedics Group IPO?

(TMDX) raised $75 million in an initial public offering (IPO) on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

When did the company's lock-up period expire?

TransMedics Group's lock-up period expired on Tuesday, October 29th. TransMedics Group had issued 5,690,000 shares in its public offering on May 2nd. The total size of the offering was $91,040,000 based on an initial share price of $16.00. Since the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Who are TransMedics Group's major shareholders?

TransMedics Group's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (1.74%), Roubaix Capital LLC (1.01%), Emerald Advisers LLC (0.99%) and Tower Research Capital LLC TRC (0.02%). Company insiders that own TransMedics Group stock include David Weill and Edwin M Kania Jr. View Institutional Ownership Trends for TransMedics Group.

Which major investors are selling TransMedics Group stock?

TMDX stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Tower Research Capital LLC TRC and Massachusetts Financial Services Co. MA. View Insider Buying and Selling for TransMedics Group.

Which major investors are buying TransMedics Group stock?

TMDX stock was bought by a variety of institutional investors in the last quarter, including Roubaix Capital LLC. Company insiders that have bought TransMedics Group stock in the last two years include David Weill and Edwin M Kania Jr. View Insider Buying and Selling for TransMedics Group.

How do I buy shares of TransMedics Group?

Shares of TMDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is TransMedics Group's stock price today?

One share of TMDX stock can currently be purchased for approximately $18.49.

How big of a company is TransMedics Group?

TransMedics Group has a market capitalization of $391.25 million. View Additional Information About TransMedics Group.

What is TransMedics Group's official website?

The official website for TransMedics Group is http://www.transmedics.com/.

How can I contact TransMedics Group?

TransMedics Group's mailing address is 200 MINUTEMAN ROAD, ANDOVER MA, 01810. The company can be reached via phone at 978-552-0900 or via email at [email protected]


MarketBeat Community Rating for TransMedics Group (NASDAQ TMDX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  26 (Vote Outperform)
Underperform Votes:  31 (Vote Underperform)
Total Votes:  57
MarketBeat's community ratings are surveys of what our community members think about TransMedics Group and other stocks. Vote "Outperform" if you believe TMDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TMDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel